InsidersTradesSigma
基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Discover the complete record of transactions filed by Myers Scott Dunseth. Officer active across 4 companies, notably Viridian Therapeutics, Inc.\DE. Cumulatively, 15 reports have been published. Split: 3 buys · 0 sell. Total volume traded: €268k. History available since 6 February 2023. The latest transaction was disclosed on 17 June 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 条申报中的 15 条
Myers Scott Dunseth is a declarant linked to Harpoon Therapeutics, Inc., Viridian Therapeutics, Inc.\DE, Zentalis Pharmaceuticals, Inc. and Dynavax Technologies CORP, with the listed role of Director at Harpoon Therapeutics, Inc. and Zentalis Pharmaceuticals, Inc., and Chief Executive Officer at Viridian Therapeutics, Inc.\DE. Across 13 filings in total, the sampled filings, from 2023-02-07 to 2025-04-30, show buy transactions of EUR 268256 and no sell transactions reported.